Stockreport

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]

Inhibikase Therapeutics, Inc.  (IKT) 
PDF Inhibikase Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ( see the details here Operator: Ladies and ge [Read more]